Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Condition:   Mesothelioma Interventions:   Drug: LMB-100;   Drug: SEL-110 Sponsor:   National Cancer Institute (NCI) Recruiting

Source: ClinicalTrials.gov - February 19, 2018 Category: Research Source Type: clinical trials